Ocular Therapeutix (OCUL) Asset Utilization Ratio (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Asset Utilization Ratio of 0.07 for Q2 2026, down 43.9% year-over-year from 0.13 in Q2 2025, and up 9.77% on a QoQ basis from 0.07 in Q1 2026.
Ocular Therapeutix (OCUL) Asset Utilization Ratio (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported Asset Utilization Ratio for 13 years, with the latest figure at 0.07 in Q2 2026.
- Asset Utilization Ratio for Q2 2026 came in at 0.07, down 43.9% year-over-year; the trailing twelve-month figure through Jun 2026 was 0.07 (down 43.9% YoY), and the FY2025 annual result was 0.08, down 54.28% from the prior year.
- Asset Utilization Ratio rose to 0.07 in Q2 2026, from 0.07 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.43 in Q2 2023 and troughed at 0.07 in Q1 2026.
- A 5-year average of 0.21 and a median of 0.14 in 2025 frame the typical range for Asset Utilization Ratio.
- The widest annual swing landed in 2022, when Asset Utilization Ratio jumped 186.87%; it then tumbled 73.39% in 2024.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.33 in 2022, then slipped by 15.69% to 0.28 in 2023, then tumbled by 52.35% to 0.13 in 2024, then sank by 36.57% to 0.09 in 2025, then retreated by 13.0% to 0.07 in 2026.
- Per Business Quant data, the three most recent Asset Utilization Ratio figures were 0.07 in Q2 2026, 0.07 in Q1 2026, and 0.09 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.07 |
| Mar 31, 2026 | 0.07 |
| Dec 31, 2025 | 0.09 |
| Sep 30, 2025 | 0.13 |
| Jun 30, 2025 | 0.13 |
| Mar 31, 2025 | 0.14 |
| Dec 31, 2024 | 0.13 |
| Sep 30, 2024 | 0.12 |
| Jun 30, 2024 | 0.12 |
| Mar 31, 2024 | 0.15 |
| Dec 31, 2023 | 0.28 |
| Sep 30, 2023 | 0.41 |
| Jun 30, 2023 | 0.43 |
| Mar 31, 2023 | 0.37 |
| Dec 31, 2022 | 0.33 |
| Sep 30, 2022 | 0.30 |
| Jun 30, 2022 | 0.28 |
| Mar 31, 2022 | 0.25 |
| Dec 31, 2021 | 0.21 |
| Sep 30, 2021 | 0.17 |